)
Edge11 Sep 2026
Texas Pacific Land Corporation: Keeper of the Permian Basin
Land once granted to a failed 19th-century railroad now generates royalties for Texas Pacific Land Corporation across the Permian Basin.
MapLight Therapeutics
MapLight Therapeutics (MPLT) investor relations material
MapLight Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary18 Sep, 2026
Company overview and business model
Clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders, leveraging a discovery platform to identify and target neural circuits causally linked to disease.
Lead candidate ML-007C-MA targets schizophrenia and Alzheimer's disease psychosis, with positive Phase 2 results and plans for Phase 3 trials.
Additional candidate ML-004 is in development for autism spectrum disorder, with Phase 2 results announced and further development under consideration.
Financial performance and metrics
Gross proceeds of approximately $150 million raised in August 2026 private placement, before fees and expenses.
55,575,719 shares of common stock outstanding as of September 1, 2026, including 2,727,511 non-voting shares.
Use of proceeds and capital allocation
No proceeds will be received from the resale of shares by selling stockholders; proceeds from warrant exercises, if any, will be received by the company.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from MapLight Therapeutics
- 13.2 million shares registered for resale after $150M private placement; no proceeds to issuer.MPLT
Registration filing - Net loss rose to $120.9M YTD; $150M raised and strong Phase 2 results support late-stage pipeline.MPLTQ2 2026
- Phase 2 ZEPHYR met its primary endpoint, showing robust efficacy and cognitive benefit with strong tolerability.MPLTStudy result
- ML-004 reduced irritability in adolescents with ASD, outperforming current therapies on safety and efficacy.MPLTStudy result
- ML-007 aims for superior tolerability and dosing convenience, with pivotal data expected in Q3 2024.MPLTStifel 2026 Virtual CNS Forum
- Q1 2026 net loss rose to $60.7M as R&D spending surged; cash reserves support operations through 2027.MPLTQ1 2026
- Shareholders to elect three directors and ratify RSM US LLP as auditor for 2026.MPLTProxy filing
- Director elections, auditor ratification, and strong governance highlight this year's proxy.MPLTProxy filing
- Novel CNS therapies in Phase 2 trials show promise for schizophrenia, ADP, and ASD.MPLTCorporate presentation
Next MapLight Therapeutics earnings date
Q3 20264 Dec, 2026
MapLight Therapeutics
Next MapLight Therapeutics earnings date
Q3 20264 Dec, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage